Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

A - Inclusion Criteria (except fluoxetine + budesonide and paracetamol arms):

1. Patients over 18 years old with the ability to provide free and informed consent
2. Acute Flu-Like symptoms < 07 days.
3. Patients with at least ONE enhancement criteria:
4. The. Age > 50 years old (does not need any of the other criteria)
5. Diabetes mellitus requiring oral medication or insulin
6. Systemic arterial hypertension requiring at least 01 oral medication fortreatment
7. Known cardiovascular diseases (heart failure, congenital heart disease, valvulardisease, coronary artery disease, cardiomyopathies under treatment, clinicallymanifest heart diseases with clinical repercussions)
8. Symptomatic and/or treated lung disease (emphysema, fibrosing diseases)
9. Patients with symptomatic asthma requiring chronic use of agents to controlsymptoms.
10. Obesity, defined as BMI > 30 kg/m2 in weight and height information provided bythe patient;
11. Transplant patients
12. Patient with stage IV chronic kidney disease or on dialysis.
13. Patient with temperature measured at screening > 38º C.
14. Patients with at least one of the following symptoms: Cough, Dyspnea,Ventilator-dependent chest pain or myalgias with limitation of daily activities (Criterion limited to 25% of randomizations)
15. Immunosuppressed patients/using corticosteroid therapy (equivalent to a maximumof 10 mg of prednisone per day) and/or immunosuppressive therapy)
16. Patients with a history of cancer in the last 5 years or currently undergoingoncological treatment
17. Patient with positive rapid test for SARS-CoV2 antigen performed on occasion of thescreening or patient with a positive SARS-CoV2 diagnostic test within 07 days of theonset of symptoms.
18. Willingness to use the proposed investigative treatment and follow theprotocol-related procedures foreseen in the research.
19. Signing the Free and Informed Consent Form before any research procedures B - Inclusion criteria for the Fluoxetine + Budesonide combination arm (07 days oftreatment - partnership with the "ANTICOV Consortium"):
20. Patients over 18 years of age with the ability to provide free and informed consent.
21. Patients treated at a Basic Health Unit of the Unified Health System (SUS) or patientstreated at emergency care units of the SUS or supplementary medicine with an acuteclinical condition compatible with COVID 19.
22. Patients over 18 years of age and a history of at least ONE of the following criteria.
23. Diabetes mellitus, heart disease, chronic kidney disease, chronic obstructivepulmonary disease, cerebrovascular diseases or patients considered to beunderweight or overweight according to the investigator's judgment (BMI ≤ 16 orBMI > 25). OR
24. Individuals aged ≥ 60 years without co-morbidities.

4. COVID-19 confirmed by molecular or antigenic test for SARS-CoV-2 within up to 24 hours prior to screening and a maximum of 2 days after sample collection.
5. Viral syndrome with or without pneumonia and arterial O2 saturation > 94%.
6. Signing the Free and Informed Consent Form before any research procedures.
7. Willingness to use the proposed investigational treatment and follow theprocedures provided for in the research.

Exclusion Criteria:

1. Negative diagnostic test for SARS-CoV2 associated with acute flu-like symptoms (patients with a negative test taken early and becoming positive a few days later areeligible, as long as they are < 07 days from the onset of flu-like symptoms);
2. Patients with an acute respiratory condition compatible with COVID-19 treated in theprimary care network and with a decision to be hospitalized;
3. Patients with acute respiratory symptoms due to other causes;
4. Dyspnea secondary to other acute and chronic respiratory causes or infections (e.g.decompensated COPD, Acute bronchitis, Pneumonia other than viral, Primary pulmonaryarterial hypertension);
5. Patients requiring hospitalization due to COVID-19 or SpO2 ≤ 93%.
6. Exclusion criteria applicable to the 7-day treatment arms:
7. Abnormal findings on physical examination: Respiratory rate ≥ 25 irm; bloodpressure < 90/ 60 mmHg or > 160/ 100 mmHg; Weight < 45 kg; recent episodes ofvomiting in the last 24 hours or diarrhea > 3 episodes in the last 24 hours orserum potassium below 3.5 mEq/L.
8. Serious injury to any organ that requires resuscitation and continuous treatment.
9. Use of chronic systemic corticosteroid therapy with prednisone equivalent dosesof > 40 mg/day
10. Ongoing immunosuppressive treatment
11. History of known pulmonary arterial hypertension or pulmonary fibrosis
12. Patients previously vaccinated with two doses for SARS-CoV-2, with the last doseadministered less than 180 days after screening; Patients with a single dose ofJanssen SARS-CoV-2 vaccine received (except Janssen vaccine) and unvaccinatedpatients can participate regardless of the period.
13. Use of serotonin reuptake inhibitors (all)
14. Patients vaccinated for SARS-CoV-2 (complete vaccination - 02 doses) within 06months of the last dose before randomization or patients who received a "booster"dose at any time before randomization.
15. For any new antiviral included in the study, prior treatment with the antiviral,presence of contraindication to its use or concomitant intake of medicationprohibited for its use.
16. Enrolled in other clinical trials with unregistered medicines or with aregistered medicine that may interact with any of the study PIs orcontraindicated as concomitant treatment in the last 3 months before screening.
17. Exclusion criteria applicable to the 10-day treatment arm: A. Chronic use of serotonin reuptake inhibitors other than sertraline B. Chronic useof corticosteroid therapy with prednisone equivalent doses of > 40 mg/day
18. Exclusion criteria applicable to the 14-day treatment arm: Patients withphenylketonuria;
19. Continued use of monoamine oxidation inhibitors (MAOIs): Phenelzine, Tranylcypromine,Selegiline, Isocarboxazid, moclobemide;
20. Patients with severe psychiatric disorders - schizophrenia, uncontrolled bipolardisorders, major depression with suicidal ideation.
21. Pregnant or breastfeeding patients;
22. History of severe ventricular cardiac arrhythmia (Ventricular Tachycardia, recoveredventricular fibrillation patients) or Long QT Syndrome;
23. Known history of decompensated heart failure (NYHA III or IV), recent myocardialinfarction (event < 90 days from screening), unstable angina, recent coronary bypasssurgery (procedure < 90 days from screening), recent stroke ( event < 90 days fromscreening), symptomatic carotid disease, or mitral or aortic stenosis of moderate tosevere intensity;
24. Surgical procedure or hospitalization planned (for other indications) to occur duringtreatment or up to 5 days after the last dose of study medication;
25. Current daily and/or uncontrolled alcohol consumption, which in the investigator'sview could compromise participation in the study;
26. History of seizures in the last month or uncontrolled seizures;
27. Clinical history of moderate to severe hepatic impairment or liver cirrhosis withChild-Pugh classification C;
28. Patients with known severe degenerative neurological diseases and/or serious mentalillnesses as assessed by the investigator;
29. Inability of the patient or representative to give consent or adhere to the proceduresproposed in the protocol;
30. Any clinical conditions, including psychiatric conditions, which in the investigator'sview could be an impediment to the use of research medications;
31. Known hypersensitivity and/or intolerance to Spirulin Platensis, Budesonide,Fluvoxamine and Fluoxetine;
32. Use of medications which have a known interaction with Spirulin platensis, Budesonide,Fluvoxamine and Fluoxetine;
33. Inability to use the medications and formulations provided for in this research;